Biocon Pharma, a subsidiary of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for generic Sacubitril/Valsartan Tablets, which treat chronic heart failure in both adults and pediatric patients over one year old. The approved strengths include 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg. This approval enhances Biocon's portfolio of complex drug products. Additionally, Biocon Pharma has also obtained USFDA approval for Daptomycin for injection (500mg vial), indicated for complicated skin infections and bloodstream infections in adults. The approvals signify Biocon's continued expansion in the US market, bolstering its offerings in diverse therapeutic areas. These regulatory nods exemplify Biocon's commitment to providing critical medications to patients in need.